NCT00983957View on ClinicalTrials.gov

Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Chronic Hepatitis C
Interventions
DRUG

BMS-790052

Tablets, Oral, 60 mg, once daily, 10 days

DRUG

Ortho Tri-Cyclen®

Tablets, Oral, once daily, 78 days

Trial Locations (3)

78752

Covance Clinical Research Unit, Inc., Austin

85283

MDS Pharma Services (US), Inc, Tempe

H4R2N6

Local Institution, Saint-Laurent

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY